Hovilpri (pritelivir) is an FDA-approved oral antiviral medicine used to treat hard-to-treat herpes simplex virus (HSV) infections in adults with weakened immune systems. It is prescribed when standard antiviral medicines, such as acyclovir, valacyclovir, or famciclovir, do not work. These infections can cause sores on the skin and moist surfaces of the body, including the lips, eyes, and genitals.
Hovilpri works differently from older antiviral medicines. It blocks two proteins, called helicase and primase, that the virus needs to multiply. This makes it effective against some HSV strains that no longer respond to existing treatments. Developed by AiCuris Anti-infective Cures AG, now part of Asahi Kasei Therapeutics, Hovilpri is the first FDA-approved HSV treatment with this new way of working in nearly 30 years.